Published in NeuroRx on April 01, 2005
Response criteria for glioma. Nat Clin Pract Oncol (2008) 2.69
Molecular imaging of gliomas with PET: opportunities and limitations. Neuro Oncol (2011) 1.40
The potential of PET/MR for brain imaging. Eur J Nucl Med Mol Imaging (2009) 1.19
Foundations of advanced magnetic resonance imaging. NeuroRx (2005) 1.11
Role of optical spectroscopy using endogenous contrasts in clinical cancer diagnosis. World J Clin Oncol (2011) 1.00
An integrated MR/PET system: prospective applications. Abdom Imaging (2009) 0.94
The translocator protein ligand [¹⁸F]DPA-714 images glioma and activated microglia in vivo. Eur J Nucl Med Mol Imaging (2012) 0.94
Non-invasive grading of brain tumours using dynamic amino acid PET imaging: does it work for 11C-methionine? Eur J Nucl Med Mol Imaging (2007) 0.93
Evaluation of treatment-associated inflammatory response on diffusion-weighted magnetic resonance imaging and 2-[18F]-fluoro-2-deoxy-D-glucose-positron emission tomography imaging biomarkers. Clin Cancer Res (2010) 0.90
[(18)F]FET-PET Imaging for Treatment and Response Monitoring of Radiation Therapy in Malignant Glioma Patients - A Review. Front Oncol (2013) 0.89
Neuroimaging: anything to do with neurotherapeutics? NeuroRx (2005) 0.83
Effect of imaging time in the magnetic resonance detection of intracerebral metastases using single dose gadobutrol. Korean J Radiol (2014) 0.80
Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in the tumors of central nervous system (CNS). J Neural Transm (Vienna) (2013) 0.78
Single burr hole endoscopic biopsy with third ventriculostomy-measurements and computer-assisted planning. Childs Nerv Syst (2011) 0.78
Specific chemotaxis of magnetically labeled mesenchymal stem cells: implications for MRI of glioma. Mol Imaging Biol (2012) 0.78
Accuracy of percentage of signal intensity recovery and relative cerebral blood volume derived from dynamic susceptibility-weighted, contrast-enhanced MRI in the preoperative diagnosis of cerebral tumours. Neuroradiol J (2015) 0.77
A systematic pipeline for the objective comparison of whole-brain spectroscopic MRI with histology in biopsy specimens from grade III glioma. Tomography (2016) 0.77
Human gene therapy and imaging in neurological diseases. Eur J Nucl Med Mol Imaging (2005) 0.77
Early [18F]FET-PET in Gliomas after Surgical Resection: Comparison with MRI and Histopathology. PLoS One (2015) 0.76
A comparison study of (11)C-methionine and (18)F-fluorodeoxyglucose positron emission tomography-computed tomography scans in evaluation of patients with recurrent brain tumors. Indian J Nucl Med (2016) 0.75
Primary diffuse large B-cell lymphoma of the dura with skull and scalp involvement: A case report and brief review of the literature. Oncol Lett (2016) 0.75
Endoscopic detection of cancer with lensless radioluminescence imaging and machine vision. Sci Rep (2016) 0.75
Tumours. Neurol Sci (2008) 0.75
The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem (1977) 11.55
Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst (1998) 5.30
Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst (2000) 5.14
Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med (1998) 5.14
Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol (2003) 4.44
A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci U S A (2003) 3.72
Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. AJNR Am J Neuroradiol (2004) 3.56
A novel triple-modality reporter gene for whole-body fluorescent, bioluminescent, and nuclear noninvasive imaging. Eur J Nucl Med Mol Imaging (2004) 3.07
Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment. Radiology (2000) 3.03
Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res (2001) 3.01
Rapid and quantitative assessment of cancer treatment response using in vivo bioluminescence imaging. Neoplasia (2001) 2.97
Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology (2004) 2.61
A multimodal nanoparticle for preoperative magnetic resonance imaging and intraoperative optical brain tumor delineation. Cancer Res (2003) 2.55
124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. J Nucl Med (2003) 2.44
Quantitative measurement of microvascular permeability in human brain tumors achieved using dynamic contrast-enhanced MR imaging: correlation with histologic grade. AJNR Am J Neuroradiol (2000) 2.27
Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected]. AJNR Am J Neuroradiol (2004) 2.21
Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med (2001) 2.18
PET: the merging of biology and imaging into molecular imaging. J Nucl Med (2000) 2.15
Integration of biochemical images of a tumor into frameless stereotaxy achieved using a magnetic resonance imaging/magnetic resonance spectroscopy hybrid data set. J Neurosurg (2004) 2.13
Distribution of liposomes into brain and rat brain tumor models by convection-enhanced delivery monitored with magnetic resonance imaging. Cancer Res (2004) 2.10
Oligodendroglioma: toward molecular definitions in diagnostic neuro-oncology. J Neuropathol Exp Neurol (2003) 2.08
Identification of early recurrence of primary central nervous system tumors by [18F]fluorodeoxyglucose positron emission tomography. Ann Neurol (1991) 2.05
PET imaging of somatostatin receptors using [68GA]DOTA-D-Phe1-Tyr3-octreotide: first results in patients with meningiomas. J Nucl Med (2001) 2.01
18F-labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis. Nucl Med Biol (2004) 1.99
Glucose utilization of cerebral gliomas measured by [18F] fluorodeoxyglucose and positron emission tomography. Neurology (1982) 1.99
Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol (2004) 1.97
Positron-emission tomography of vector-mediated gene expression in gene therapy for gliomas. Lancet (2001) 1.94
Cerebral gangliogliomas: preoperative grading using FDG-PET and 201Tl-SPECT. AJNR Am J Neuroradiol (1998) 1.87
Histopathology, classification, and grading of gliomas. Glia (1995) 1.84
Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study. J Neurosurg (2004) 1.78
Volumetric assessment of glioma removal by intraoperative high-field magnetic resonance imaging. Neurosurgery (2004) 1.77
Noninvasive MR imaging of magnetically labeled stem cells to directly identify neovasculature in a glioma model. Blood (2004) 1.76
Dissecting tumor maintenance requirements using bioluminescence imaging of cell proliferation in a mouse glioma model. Nat Med (2004) 1.76
Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities. Cancer Res (2000) 1.74
Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur J Nucl Med (2001) 1.71
Diffusion-weighted imaging in the follow-up of treated high-grade gliomas: tumor recurrence versus radiation injury. AJNR Am J Neuroradiol (2004) 1.69
Magnetic resonance image-guided proteomics of human glioblastoma multiforme. J Magn Reson Imaging (2003) 1.69
Pathways leading to glioblastoma multiforme: a molecular analysis of genetic alterations in 65 astrocytic tumors. J Neurosurg (1994) 1.67
Glioma classification: a molecular reappraisal. Am J Pathol (2001) 1.65
Classification of biopsy-confirmed brain tumors using single-voxel MR spectroscopy. AJNR Am J Neuroradiol (1999) 1.64
Extensive distribution of liposomes in rodent brains and brain tumors following convection-enhanced delivery. J Neurooncol (2004) 1.61
Dynamic contrast-enhanced magnetic resonance imaging as a surrogate marker of tumor response to anti-angiogenic therapy in a xenograft model of glioblastoma multiforme. J Magn Reson Imaging (2002) 1.59
Molecular imaging of temporal dynamics and spatial heterogeneity of hypoxia-inducible factor-1 signal transduction activity in tumors in living mice. Cancer Res (2004) 1.59
Malignant glioma: who benefits from adjuvant chemotherapy? Ann Neurol (1998) 1.56
11C-methionine PET for differential diagnosis of low-grade gliomas. Neurology (1998) 1.56
Peritumoral brain regions in gliomas and meningiomas: investigation with isotropic diffusion-weighted MR imaging and diffusion-tensor MR imaging. Radiology (2004) 1.54
Preoperative blood oxygen level-dependent functional magnetic resonance imaging in patients with primary brain tumors: clinical application and outcome. Neurosurgery (2004) 1.53
The in vivo metabolic pattern of low-grade brain gliomas: a positron emission tomographic study using 18F-fluorodeoxyglucose and 11C-L-methylmethionine. Neurosurgery (1997) 1.50
Imaging-guided convection-enhanced delivery and gene therapy of glioblastoma. Ann Neurol (2003) 1.50
Delineation of brain tumor extent with [11C]L-methionine positron emission tomography: local comparison with stereotactic histopathology. Clin Cancer Res (2004) 1.48
FDG-PET in differentiating lymphoma from nonmalignant central nervous system lesions in patients with AIDS. J Nucl Med (1993) 1.47
Noninvasive imaging of spontaneous retinoblastoma pathway-dependent tumors in mice. Cancer Res (2002) 1.46
Neuroimaging of juvenile pilocytic astrocytomas: an enigma. Radiology (1993) 1.44
Optimal cutoff levels of F-18 fluorodeoxyglucose uptake in the differentiation of low-grade from high-grade brain tumors with PET. Radiology (1995) 1.42
3D MRSI for resected high-grade gliomas before RT: tumor extent according to metabolic activity in relation to MRI. Int J Radiat Oncol Biol Phys (2004) 1.38
Comparison of 18F-FDG and 11C-methionine for PET-guided stereotactic brain biopsy of gliomas. J Nucl Med (2004) 1.35
Interobserver variability in the radiological assessment of response to chemotherapy in glioma. Neurology (2003) 1.35
MR-spectroscopy guided target delineation for high-grade gliomas. Int J Radiat Oncol Biol Phys (2001) 1.35
Histopathological-molecular genetic correlations in referral pathologist-diagnosed low-grade "oligodendroglioma". J Neuropathol Exp Neurol (2002) 1.35
Pretreatment prediction of brain tumors' response to radiation therapy using high b-value diffusion-weighted MRI. Neoplasia (2004) 1.32
Lhermitte-Duclos disease: assessment with MR imaging, positron emission tomography, single-photon emission CT, and MR spectroscopy. AJNR Am J Neuroradiol (2001) 1.32
Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value. Eur J Nucl Med Mol Imaging (2004) 1.30
Value of O-(2-[18F]fluoroethyl)- L-tyrosine PET for the diagnosis of recurrent glioma. Eur J Nucl Med Mol Imaging (2004) 1.28
Prediction of survival in glioma patients by means of positron emission tomography. J Neurosurg (1985) 1.27
Volume reconstruction techniques improve the correlation between histological and in vivo tumor volume measurements in mouse models of human gliomas. J Neurooncol (2004) 1.27
Quantitation of cell number by a positron emission tomography reporter gene strategy. Mol Imaging Biol (2004) 1.26
Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine. J Nucl Med (1998) 1.25
The use of 19F spectroscopy and diffusion-weighted MRI to evaluate differences in gene-dependent enzyme prodrug therapies. Mol Ther (2004) 1.25
Methionine positron emission tomography for differentiation of recurrent brain tumor and radiation necrosis after stereotactic radiosurgery--in malignant glioma. Ann Nucl Med (2004) 1.25
Screening for cerebral metastases with FDG PET in patients undergoing whole-body staging of non-central nervous system malignancy. Radiology (2003) 1.24
Brain metastases from non-central nervous system tumors: evaluation with PET. Radiology (1993) 1.24
Imaging transcriptional regulation of p53-dependent genes with positron emission tomography in vivo. Proc Natl Acad Sci U S A (2001) 1.22
White matter fiber tracking in patients with space-occupying lesions of the brain: a new technique for neurosurgical planning? Neuroimage (2003) 1.21
Correlation between magnetic resonance spectroscopy imaging and image-guided biopsies: semiquantitative and qualitative histopathological analyses of patients with untreated glioma. Neurosurgery (2001) 1.20
The sensitivity and specificity of FDG PET in distinguishing recurrent brain tumor from radionecrosis in patients treated with stereotactic radiosurgery. Int J Cancer (2001) 1.20
Intraoperative high-field-strength MR imaging: implementation and experience in 200 patients. Radiology (2004) 1.19
A new approach for analyzing proton magnetic resonance spectroscopic images of brain tumors: nosologic images. Nat Med (2000) 1.17
Identification of MRI and 1H MRSI parameters that may predict survival for patients with malignant gliomas. NMR Biomed (2004) 1.17
Plasticity of language networks in patients with brain tumors: a positron emission tomography activation study. Ann Neurol (2001) 1.17
Usefulness of 11C-methionine PET in the evaluation of brain lesions that are hypo- or isometabolic on 18F-FDG PET. Eur J Nucl Med Mol Imaging (2002) 1.16
MRI of mouse models for gliomas shows similarities to humans and can be used to identify mice for preclinical trials. Neoplasia (2002) 1.08
Diffusion-tensor imaging-guided tracking of fibers of the pyramidal tract combined with intraoperative cortical stimulation mapping in patients with gliomas. J Neurosurg (2004) 1.08
Diffusion-weighted MRI features of brain abscess and cystic or necrotic brain tumors: comparison with conventional MRI. Clin Imaging (2002) 1.07
18F-FDG PET of gliomas at delayed intervals: improved distinction between tumor and normal gray matter. J Nucl Med (2004) 1.07
18-Fluorodeoxyglucose uptake and survival of patients with suspected recurrent malignant glioma. Cancer (1997) 1.07
Antiangiogenic therapy by local intracerebral microinfusion improves treatment efficiency and survival in an orthotopic human glioblastoma model. Clin Cancer Res (2004) 1.06
Methyl-[11C]- l-methionine uptake as measured by positron emission tomography correlates to microvessel density in patients with glioma. Eur J Nucl Med Mol Imaging (2003) 1.06
[18F]FLT; portrait of a proliferation marker. Eur J Nucl Med Mol Imaging (2002) 1.06
Validation of a method for automatic image fusion (BrainLAB System) of CT data and 11C-methionine-PET data for stereotactic radiotherapy using a LINAC: first clinical experience. Int J Radiat Oncol Biol Phys (2003) 1.05
Integration of sulcal and functional information for multimodal neuronavigation. J Neurosurg (2002) 1.05
Discrepancy between lesion distributions on methionine PET and MR images in patients with glioblastoma multiforme: insight from a PET and MR fusion image study. J Neurol Neurosurg Psychiatry (2004) 1.04
Perfusion MRI of U87 brain tumors in a mouse model. Magn Reson Med (2004) 1.03
Proton magnetic resonance spectroscopy imaging in the evaluation of patients undergoing gamma knife surgery for Grade IV glioma. J Neurosurg (2004) 1.02
Studies of primary central nervous system lymphoma with fluorine-18-fluorodeoxyglucose positron emission tomography. J Nucl Med (1992) 1.01
Characterizing tumors using metabolic imaging: PET imaging of cellular proliferation and steroid receptors. Neoplasia (2000) 1.01
Correlation of glucose consumption and tumor cell density in astrocytomas. A stereotactic PET study. J Neurosurg (1993) 1.01
Differentiation between high-grade glioma and metastatic brain tumor using single-voxel proton MR spectroscopy. Eur Radiol (2001) 1.01
In vivo imaging of glucose consumption and lactate concentration in human gliomas. Ann Neurol (1992) 1.00
Regional kinetic constants and cerebral metabolic rate for glucose in normal human volunteers determined by dynamic positron emission tomography of [18F]-2-fluoro-2-deoxy-D-glucose. J Cereb Blood Flow Metab (1984) 1.00
Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov (2010) 4.55
Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias. J Nucl Med (2008) 2.92
Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. Arch Neurol (2005) 2.65
The nucleus accumbens: a target for deep brain stimulation in obsessive-compulsive- and anxiety-disorders. J Chem Neuroanat (2003) 2.08
Interaction of the cytosolic domains of sorLA/LR11 with the amyloid precursor protein (APP) and beta-secretase beta-site APP-cleaving enzyme. J Neurosci (2006) 1.83
Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease. Arch Neurol (2005) 1.82
Imaging markers for Alzheimer disease: which vs how. Neurology (2013) 1.76
Effectiveness and safety of 18F-FDG PET in the evaluation of dementia: a review of the recent literature. J Nucl Med (2011) 1.67
Imaging-guided convection-enhanced delivery and gene therapy of glioblastoma. Ann Neurol (2003) 1.50
Delineation of brain tumor extent with [11C]L-methionine positron emission tomography: local comparison with stereotactic histopathology. Clin Cancer Res (2004) 1.48
18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors. J Nucl Med (2005) 1.44
Brain inflammation is induced by co-morbidities and risk factors for stroke. Brain Behav Immun (2011) 1.44
Fast and robust registration of PET and MR images of human brain. Neuroimage (2004) 1.41
Endovascular gamma irradiation of femoropopliteal de novo stenoses immediately after PTA: interim results of prospective randomized controlled trial. Radiology (2002) 1.38
Current diagnosis and treatment of spondylodiscitis. Dtsch Arztebl Int (2008) 1.30
Femoral pseudoaneurysms: management with percutaneous thrombin injections--success rates and effects on systemic coagulation. Radiology (2003) 1.29
Crossed cerebellar diaschisis in acute human stroke: a PET study of serial changes and response to supratentorial reperfusion. J Cereb Blood Flow Metab (2005) 1.29
Subthalamic nucleus stimulation restores glucose metabolism in associative and limbic cortices and in cerebellum: evidence from a FDG-PET study in advanced Parkinson's disease. J Cereb Blood Flow Metab (2004) 1.28
SNM practice guideline for dopamine transporter imaging with 123I-ioflupane SPECT 1.0. J Nucl Med (2011) 1.28
Ubiquilin 1 modulates amyloid precursor protein trafficking and Abeta secretion. J Biol Chem (2006) 1.26
Orbitofrontal dysfunction related to both apathy and disinhibition in frontotemporal dementia. Dement Geriatr Cogn Disord (2006) 1.25
The right inferior frontal gyrus and poststroke aphasia: a follow-up investigation. Stroke (2007) 1.25
Predominant ventromedial frontopolar metabolic impairment in frontotemporal dementia. Neuroimage (2003) 1.23
Neural correlates of anosognosia for cognitive impairment in Alzheimer's disease. Hum Brain Mapp (2006) 1.21
A European multicentre PET study of fibrillar amyloid in Alzheimer's disease. Eur J Nucl Med Mol Imaging (2012) 1.21
Deep brain stimulation of the subthalamic nucleus does not increase the striatal dopamine concentration in parkinsonian humans. Mov Disord (2003) 1.14
From the left to the right: How the brain compensates progressive loss of language function. Brain Lang (2006) 1.09
The complementary role of the cerebral hemispheres in recovery from aphasia after stroke: a critical review of literature. Brain Inj (2014) 1.07
Brain receptor imaging. J Nucl Med (2006) 1.06
Direct demonstration of transcallosal disinhibition in language networks. J Cereb Blood Flow Metab (2006) 1.06
Effects of repetitive transcranial magnetic stimulation in aphasic stroke: a randomized controlled pilot study. Stroke (2010) 1.06
Methyl-[11C]- l-methionine uptake as measured by positron emission tomography correlates to microvessel density in patients with glioma. Eur J Nucl Med Mol Imaging (2003) 1.06
Volumetry of [(11)C]-methionine PET uptake and MRI contrast enhancement in patients with recurrent glioblastoma multiforme. Eur J Nucl Med Mol Imaging (2010) 1.03
Optimized data preprocessing for multivariate analysis applied to 99mTc-ECD SPECT data sets of Alzheimer's patients and asymptomatic controls. J Cereb Blood Flow Metab (2010) 1.03
Use of 11C-methionine PET to monitor the effects of temozolomide chemotherapy in malignant gliomas. Eur J Nucl Med Mol Imaging (2006) 1.03
Regional cerebral metabolism in early Alzheimer's disease with clinically significant apathy or depression. Biol Psychiatry (2005) 1.02
Summary metrics to assess Alzheimer disease-related hypometabolic pattern with 18F-FDG PET: head-to-head comparison. J Nucl Med (2012) 1.02
18FDG PET in vascular dementia: differentiation from Alzheimer's disease using voxel-based multivariate analysis. J Cereb Blood Flow Metab (2006) 1.02
Imaging epigenetic regulation by histone deacetylases in the brain using PET/MRI with ¹⁸F-FAHA. Neuroimage (2012) 1.01
MR imaging of claustrophobic patients in an open 1.0T scanner: motion artifacts and patient acceptability compared with closed bore magnets. Eur J Radiol (2007) 1.01
[18F]DPA-714: direct comparison with [11C]PK11195 in a model of cerebral ischemia in rats. PLoS One (2013) 1.00
Staging of the cognitive decline in Alzheimer's disease: insights from a detailed neuropsychological investigation of mild cognitive impairment and mild Alzheimer's disease. Int J Geriatr Psychiatry (2011) 0.98
Detection of presenilin-1 homodimer formation in intact cells using fluorescent lifetime imaging microscopy. Biochem Biophys Res Commun (2005) 0.97
Cholinergic system function and cognition in mild cognitive impairment. Neurobiol Aging (2010) 0.97
Decomposition of metabolic brain clusters in the frontal variant of frontotemporal dementia. Neuroimage (2005) 0.97
Molecular imaging in the diagnosis of Alzheimer's disease: visual assessment of [11C]PIB and [18F]FDDNP PET images. J Neurol Neurosurg Psychiatry (2010) 0.97
Acetylsalicylic acid pretreatment, concomitant heparin therapy and the risk of early intracranial hemorrhage following systemic thrombolysis for acute ischemic stroke. Cerebrovasc Dis (2003) 0.95
Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients with glioma. J Nucl Med (2009) 0.94
[11C]-L-methionine positron emission tomography in the management of children and young adults with brain tumors. J Neurooncol (2009) 0.94
The striatal dopaminergic deficit is dependent on the number of mutant alleles in a family with mutations in the parkin gene: evidence for enzymatic parkin function in humans. Neurosci Lett (2002) 0.94
Age and ApoE genotype interaction in Alzheimer's disease: an FDG-PET study. Psychiatry Res (2004) 0.94
Where in-vivo imaging meets cytoarchitectonics: the relationship between cortical thickness and neuronal density measured with high-resolution [18F]flumazenil-PET. Neuroimage (2010) 0.94
Essential language function of the right hemisphere in brain tumor patients. Ann Neurol (2005) 0.93
Metabolic rates in small brain nuclei determined by high-resolution PET. J Nucl Med (2004) 0.93
Functional interactions of the entorhinal cortex: an 18F-FDG PET study on normal aging and Alzheimer's disease. J Nucl Med (2004) 0.93
Efficient principal component analysis for multivariate 3D voxel-based mapping of brain functional imaging data sets as applied to FDG-PET and normal aging. Hum Brain Mapp (2003) 0.93
Evaluation of primary brain tumors using 11C-methionine PET with reference to a normal methionine uptake map. J Nucl Med (2007) 0.92
Interesting image. PET imaging of a butterfly glioblastoma. Clin Nucl Med (2010) 0.92
Mutations in amyloid precursor protein affect its interactions with presenilin/gamma-secretase. Mol Cell Neurosci (2009) 0.92
Signal peptide peptidase (SPP) dimer formation as assessed by fluorescence lifetime imaging microscopy (FLIM) in intact cells. Mol Neurodegener (2006) 0.90
Voriconazole brain tissue levels in rhinocerebral aspergillosis in a successfully treated young woman. Int J Antimicrob Agents (2006) 0.89
Multimodal microglia imaging of fiber tracts in acute subcortical stroke. Ann Neurol (2009) 0.89
Patient-tailored, imaging-guided, long-term temozolomide chemotherapy in patients with glioblastoma. Mol Imaging (2010) 0.89
Experimental radiofrequency ablation near the portal and the hepatic veins in pigs: differences in efficacy of a monopolar ablation system. J Surg Res (2006) 0.88
Imaging of non- or very subtle contrast-enhancing malignant gliomas with [¹¹C]-methionine positron emission tomography. Mol Imaging (2011) 0.88
Right amygdalar and temporofrontal activation during autobiographic, but not during fictitious memory retrieval. Behav Neurol (2000) 0.88
Image quality of digital direct flat-panel mammography versus an analog screen-film technique using a phantom model. AJR Am J Roentgenol (2007) 0.88
On the multivariate nature of brain metabolic impairment in Alzheimer's disease. Neurobiol Aging (2007) 0.87
Reduced glucose metabolism in temporo-parietal cortices of women with borderline personality disorder. Psychiatry Res (2005) 0.87
Diagnostic accuracy of markers for prodromal Alzheimer's disease in independent clinical series. Alzheimers Dement (2013) 0.86
Noninvasive brain stimulation for treatment of right- and left-handed poststroke aphasics. Cerebrovasc Dis (2013) 0.86
Bilateral transcranial direct current stimulation modulates activation-induced regional blood flow changes during voluntary movement. J Cereb Blood Flow Metab (2011) 0.85
[¹¹C]-(R)PK11195 tracer kinetics in the brain of glioma patients and a comparison of two referencing approaches. Eur J Nucl Med Mol Imaging (2013) 0.85
Feasibility of peripheral contrast-enhanced magnetic resonance angiography at 3.0 Tesla with a hybrid technique: comparison with digital subtraction angiography. Invest Radiol (2008) 0.85
Magnetic resonance imaging in an orthotopic rat model: blockade of epidermal growth factor receptor with EMD72000 inhibits human pancreatic carcinoma growth. Int J Cancer (2005) 0.83
Fluorescence lifetime imaging microscopy (FLIM) detects stimulus-dependent phosphorylation of the low density lipoprotein receptor-related protein (LRP) in primary neurons. Biochem Biophys Res Commun (2006) 0.83
Volumetry of [¹¹C]-methionine positron emission tomographic uptake as a prognostic marker before treatment of patients with malignant glioma. Mol Imaging (2012) 0.83
A Contribution to solve the problem of the need for consolidative radiotherapy after intensive chemotherapy in advanced stages of Hodgkin's lymphoma--analysis of a quality control program initiated by the radiotherapy reference center of the German Hodgkin Study Group (GHSG). Int J Radiat Oncol Biol Phys (2007) 0.83
Initial and serial evoked potentials in cerebrovascular critical care patients. J Clin Neurophysiol (2006) 0.83
Changes in callosal motor fiber integrity after subcortical stroke of the pyramidal tract. J Cereb Blood Flow Metab (2012) 0.83
Neuroimaging-guided rTMS of the left inferior frontal gyrus interferes with repetition priming. Neuroimage (2005) 0.82
Neuroimaging in patients with gliomas. Semin Neurol (2008) 0.82
Improved work-up procedure for the production of [(18)F]flumazenil and first results of its use with a high-resolution research tomograph in human stroke. Nucl Med Biol (2009) 0.82
Centralized radiation oncologic review of cross-sectional imaging of Hodgkin's disease leads to significant changes in required involved field-results of a quality assurance program of the German Hodgkin Study Group. Int J Radiat Oncol Biol Phys (2004) 0.81
Hybrid contrast-enhanced MR angiography of pelvic and lower extremity vasculature at 3.0 T: initial experience. Eur J Radiol (2008) 0.81
Perrault Syndrome with progressive nervous system involvement. Clin Nucl Med (2008) 0.81
Effects of the anti-VEGF monoclonal antibody bevacizumab in a preclinical model and in patients with refractory and multiple relapsed Hodgkin lymphoma. J Immunother (2009) 0.81
Early signs of VCP-related frontotemporal dementia: a neuropsychological, FDG-PET and fMRI study. J Neurol (2010) 0.80
Non-pharmacological interventions and neuroplasticity in early stage Alzheimer's disease. Expert Rev Neurother (2013) 0.80
Alzheimer Disease Biomarkers as Outcome Measures for Clinical Trials in MCI. Alzheimer Dis Assoc Disord (2015) 0.80
Histone deacetylase class II and acetylated core histone immunohistochemistry in human brains with Huntington's disease. Brain Res (2013) 0.80
Pathomorphological changes after radiofrequency ablation in the liver. Pathol Int (2010) 0.80
Focal nodular hyperplasia of the liver in longterm survivors of neuroblastoma: how much diagnostic imaging is necessary? Eur J Radiol (2009) 0.80